Brilocaine®-adrenaline (Solution) Instructions for Use
ATC Code
N01BB58 (Articaine in combination with other drugs)
Active Substances
Articaine (Rec.INN registered by WHO)
Epinephrine (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Local anesthetic for use in dentistry
Pharmacotherapeutic Group
Anesthetics; local anesthetics; amides
Pharmacological Action
A combined medicinal product that exerts a local anesthetic effect.
Articaine is a local anesthetic of the amide type from the thiophene series. Its mechanism of action is due to the stabilization of neuronal membranes and the prevention of the generation and conduction of nerve impulses.
Epinephrine is an adrenomimetic. It causes vasoconstriction at the site of injection, which reduces the absorption of articaine and prolongs the duration of the local anesthetic effect.
The onset of action is 0.5-3 minutes, and the duration of action is 45 minutes.
Indications
Infiltration and conduction anesthesia (including in dentistry – tooth extraction, cavity filling, tooth preparation for crowns).
ICD codes
| ICD-10 code | Indication |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution
Infiltration anesthesia: tonsillectomy (for each tonsil) – 5-10 ml; reduction of fractures – 5-20 ml; perineal suture – 5-15 ml.
Conduction anesthesia: Oberst’s anesthesia – 2-4 ml, retrobulbar – 1-2 ml, intercostal – 2-4 ml (per segment), paravertebral – 5-10 ml, peridural (epidural) – 10-30 ml, sacral – 10-30 ml, trigeminal nerve block – 1-5 ml, stellate ganglion block – 5-10 ml, brachial plexus block – 10-30 ml (supraclavicular or axillary approach), external genitalia block – 7-10 ml (per side), paracervical block – 6-10 ml (per side).
For uncomplicated extraction of upper jaw teeth in a non-inflammatory stage, inject under the mucous membrane in the area of the transitional fold – vestibular depot 1.7 ml per tooth, if necessary – additionally 1-1.7 ml; palatal incision or suture – palatal depot 0.1 ml.
For extraction of lower jaw premolars (5-5) in an uncomplicated stage, infiltration anesthesia provides an effect equivalent to conduction anesthesia.
For cavity preparation and tooth preparation for crowns, except for lower jaw molars – vestibular injection of 0.5-1.7 ml per tooth. The maximum dose is 7 mg/kg.
Adverse Reactions
From the central nervous system (dose-dependent): headache, impaired consciousness (up to loss of consciousness); respiratory disorders (up to apnea); tremor, muscle twitching, convulsions.
From the digestive system: nausea, vomiting, diarrhea.
From the sensory organs: rarely – transient visual disturbances (up to blindness), diplopia.
From the cardiovascular system: decreased blood pressure, tachycardia, bradycardia, arrhythmia.
Allergic reactions: skin hyperemia and itching, conjunctivitis, rhinitis, angioedema of varying severity (including edema of the upper and/or lower lip and/or cheeks, laryngeal edema with difficulty swallowing, urticaria, difficulty breathing), anaphylactic shock.
Local reactions: swelling or inflammation at the injection site, appearance of ischemic zones at the injection site (up to the development of tissue necrosis – in case of accidental intravascular injection); nerve damage (up to the development of paralysis) – occurs only due to improper injection technique.
Contraindications
B12-deficiency anemia; methemoglobinemia; paroxysmal ventricular tachycardia; atrial tachyarrhythmia; angle-closure glaucoma; hypoxia; intolerance to sulfogroups (especially in bronchial asthma); hypersensitivity to the components of the combination.
With caution: cholinesterase deficiency, renal failure, bronchial asthma, diabetes mellitus, hyperthyroidism, arterial hypertension, children’s age (under 4 years – efficacy and safety have not been established).
For paracervical block: preeclampsia, bleeding in the third trimester of pregnancy, amnionitis.
Use in Pregnancy and Lactation
It does not have a harmful effect on the fetus (except for possible bradycardia) with any technique of application and dosage.
During lactation, there is no need to interrupt breastfeeding, as clinically significant concentrations of articaine are not detected in breast milk.
Use in Renal Impairment
With caution in renal failure.
Pediatric Use
With caution in children (under 4 years of age – efficacy and safety have not been established).
Special Precautions
Do not administer intravenously! To avoid intravascular injection, an aspiration test must be performed. The injection pressure should correspond to the sensitivity of the tissue.
Do not inject into an inflamed area.
Food intake is possible only after the sensitivity is restored.
Effect on the ability to drive vehicles and mechanisms
The patient’s admission to driving vehicles or engaging in activities requiring high mental and motor reactions is determined by the doctor.
Drug Interactions
Tricyclic antidepressants, MAO inhibitors enhance the hypertensive effect.
The local anesthetic effect of articaine is enhanced and prolonged by vasoconstrictors.
Non-selective beta-blockers increase the risk of hypertensive crisis and severe bradycardia.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for injection 40 mg+0.005 mg/1 ml: cartridges 1.7 ml or 1.8 ml 5, 10, 15, 20, 25, 30, 40, 50 or 100 pcs.; amp. 2 ml 5, 10, 15, 20, 25 or 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Brilocaine®-adrenaline | Solution for injection 40 mg+0.005 mg/1 ml: cartridges 1.7 ml or 1.8 ml 5, 10, 15, 20, 25, 30, 40, 50 or 100 pcs.; amp. 2 ml 5, 10, 15, 20, 25 or 50 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection in the form of a colorless, transparent liquid with a characteristic odor.
| 1 ml | |
| Epinephrine bitartrate | 0.009 mg, |
| Calculated as epinephrine (adrenaline) | 0.005 mg |
| Articaine hydrochloride | 40 mg |
Excipients: sodium disulfite – 0.5 mg, sodium chloride – 1.6 mg, disodium edetate – 0.25 mg, sodium hydroxide – to adjust pH to 5.0, water for injection – up to 1 ml.
1.7 ml – glass cartridges (5) – contour cell packaging (1) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (2) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (3) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (4) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (5) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (10) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (1) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (2) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (3) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (4) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (5) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (10) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (1) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (2) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (3) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (4) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (5) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (10) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (1) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (2) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (3) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (4) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (5) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (10) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (1) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (2) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (3) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (4) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (5) – cardboard boxes.
2 ml – glass ampoules (5) – contour cell packaging (10) – cardboard boxes.
Solution for injection 40 mg+0.01 mg/1 ml: cartridges 1.7 ml or 1.8 ml 5, 10, 15, 20, 25, 30, 40, 50 or 100 pcs.; amp. 2 ml 5, 10, 15, 20, 25 or 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Brilocaine®-Adrenaline Forte | Solution for injection 40 mg+0.01 mg/1 ml: cartridges 1.7 ml or 1.8 ml 5, 10, 15, 20, 25, 30, 40, 50 or 100 pcs.; amp. 2 ml 5, 10, 15, 20, 25 or 50 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection in the form of a colorless, transparent liquid with a characteristic odor.
| 1 ml | |
| Epinephrine bitartrate | 0.018 mg, |
| Calculated as epinephrine (adrenaline) | 0.01 mg |
| Articaine hydrochloride | 40 mg |
Excipients: sodium disulfite – 0.5 mg, sodium chloride – 1.6 mg, disodium edetate – 0.25 mg, sodium hydroxide – to adjust pH to 5.0, water for injection – up to 1 ml.
1.7 ml – glass cartridges (5) – contour cell packaging (1) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (2) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (3) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (4) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (5) – cardboard boxes.
1.7 ml – glass cartridges (5) – contour cell packaging (10) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (1) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (2) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (3) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (4) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (5) – cardboard boxes.
1.7 ml – glass cartridges (10) – contour cell packaging (10) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (1) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (2) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (3) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (4) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (5) – cardboard boxes.
1.8 ml – glass cartridges (5) – contour cell packaging (10) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (1) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (2) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (3) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (4) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (5) – cardboard boxes.
1.8 ml – glass cartridges (10) – contour cell packaging (10) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (1) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (2) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (3) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (4) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (5) – cardboard boxes.
2 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packaging (10) – cardboard boxes.
Ingavirin capsules 90mg, 10pcs
Daivobet, ointment, 30g
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
No-spa pills 40mg, 64pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Nootropil pills 800mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Phenibut-Vertex pills 250mg, 20pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs 